BNET Industries
Barr Pharmaceuticals Inc. (BRL) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $2.5B
- Profit
- Dec 31 2007
- $128.3M
- Market Cap
- Aug 27 2008
- $7.3B
Latest News and Analysis
Merger Watch: Barr Pharmaceuticals - Teva Pharmaceutical
The M & A Researcher submits: First, this August 14 Financial Times article will be referenced as it essentially echoes this publication's original assessment of the Barr Pharmaceuticals BRL - Teva Pharmaceutical TEVA transaction upon announcement last month. Of particular interest in this piece are the following passages from...
Generic Drugs: Industry Snapshot
Mike Havrilla submits:Global Generic Drug Industry: Benchmark Comps Global Generic Drug Industry: Top 5 Companies by Market Cap Global Generic Drugs: Top 5 Companies by Stock Performance The accompanying tables provide a snapshot of my 38-company Global Generic Drug Index, which is rapidly consolidating amidst a flurry of recent M&A activity --...
Sector and Stock Performance Since Oil's Peak
Hickey and Walters Bespoke submit: Since oil peaked using closing prices on July 3rd, the commodity is down about 21%. Over the same time period, the average stock in the S&P 500 is up 6.11%. Below we highlight the average performance of stocks in each sector since oil's...
Big Pharma?s Healthy Appetite for Acquisitions
Santosh Sankar submits: Healthcare, more specifically Pharma is showing an appetite for deal making as four major companies are courting potential acquisitions. This hunger signals a change in the environment as signs of consolidation surface. If we look at this year’s activity, IPOs were at an all time low and...
Barr Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Barr Pharmaceuticals Inc. BRL Q2 FY08 Earnings Call
Board and Executive Compensation in S&P 500
Richard Shaw QVM Group submits: Executive compensation and board largess with high paid executives is a hot topic recently. That spurred us to look comprehensively at some factual comparative data on the total cost of boards of directors and top executive teams among the S&P 500 companies (proxy SPY...
Watch for More Coming Biotech Acquisitions
Zacks.com submits: With M&A activity finally going strong within the pharma/biotech markets, we were interested in speaking to Zacks senior pharma & biotech analyst Jason Napodano, CFA about how he sees this latest round of mergers taking shape within the overall drug industry in general. Jason,...
S&P 500's Best and Worst Net Income Change
Richard Shaw QVM Group submits: The vast majority of S&P 500 companies proxy SPY or IVV are profitable on a 12-month basis, but some have profits strongly on the rise and others have profits strongly on the fall. This article presents the 20 companies with the highest ratio...
Barr Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Barr Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Barr Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Barr Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Barr Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
Barr Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
Barr Pharmaceuticals Q3 2007 Earnings Call Transcript
Barr Pharmaceuticals Q3 2007 Earnings Call Transcript
Barr Pharmaceuticals Q2 2007 Earnings Call Transcript
Barr Pharmaceuticals Q2 2007 Earnings Call Transcript
Zacks Challenge Top Player Interview features Barr Pharmaceuticals, Inc., Zoltek Companies, Inc. and Brightpoint, Inc
CHICAGO -- Zacks.com introduces its Third Quarter Challenge top player interviews, which feature insights from the leaders of the Zacks Simulator game. The Simulator allows investors to prove their stock picking abilities by competing directly against other players for prizes worth thousands of the dollars.
Barr Pharmaceuticals, Inc. Conference Call to Discuss the Non-Final Rejection Notice Related to SEASONALE - Research and Markets Offers a Brief of 'Barr Pharmaceuticals, Inc.' Conference Call
DUBLIN, Ireland -- The Barr Pharmaceuticals, Inc. (NYSE:BRL) Corporate Conference Call took place on 12-May-06 9:00am ET.
Q3 2006 Barr Pharmaceuticals, Inc. Earnings Conference Call - Research and Markets Offers a Brief of 'Barr Pharmaceuticals, Inc.' Conference Call
DUBLIN, Ireland -- The Barr Pharmaceuticals, Inc. (NYSE:BRL) Corporate Conference Call took place on 4-May-06 8:30am ET.
Leerink Swann & Company Initiates Coverage of Barr Pharmaceuticals, Inc. (NYSE: BRL) Mylan Laboratories Inc. (NYSE: MYL)
This morning, Senior Generic Pharmaceutical Analyst, William F. Sawyer, initiated coverage of Barr Pharmaceuticals (NYSE: BRL) with an Outperform rating and Mylan Laboratories Inc. (NYSE: MYL) with a Market Perform rating. He bases his investment rating for Barr on his view that solid operating performance from Barr's generic and branded...
Savient Pharmaceuticals Finalizes Agreement for the Settlement of Mircette® Litigation; Transaction Terminates Patent Litigation and Results in $13.75 Million Payment To Savient
EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. ("Savient") (NASDAQ: SVNTE), an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, announced today that it has concluded with Barr Pharmaceuticals, Inc. ("Barr") (NYSE: BRL), Organon USA Inc. and...
FDA says it will decide on Plan B.(Food and Drug Administration)
WASHINGTON -- The Food and Drug Administration is committed to ruling on whether Plan B, an emergency contraceptive manufactured by Barr Pharmaceuticals Inc., will be switched to over-the-counter status. The drug's status has been the subject of cont WASHINGTON -- The Food and Drug Administration is...
Research and Markets: Barr Pharmaceuticals Inc. - Pharmatrack
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c10322) has announced the addition of Barr Pharmaceuticals Inc. - Pharmatrack to their offering
- Next »
- page 1 of 2
- « Previous
Sort byClose
View by Content TypeClose
- Incorporated: 1970
- CEO: Mr. Bruce L. Downey
Barr Pharmaceuticals is a specialty pharmaceutical company. Co. develops, manufactures and markets generic and proprietary pharmaceutical products. Co.'s generic product portfolio includes solid oral dosage forms, injectables and cream/ointment products. At Dec 31 2007, Co. marketed for sale in the U.S., about 245 different dosage forms and strengths of about 120 different generic pharmaceutical products, including 25 oral contraceptive products; and in Europe and the rest of the world, approximately 1,025 generic pharmaceutical products. Co.'s products include SEASONIQUE®, PLAN B? and PARAGARD® T 380A.
Key Competitors
Barr Pharmaceuticals Inc. Company Info
Board of Directors
Mr. Bruce L. Downey
Chairman
Mr. George P. Stephan
Mr. Harold N. Chefitz
Mr. Richard R. Frankovic
Mr. Peter R. Seaver
Mr. James S. Gilmore III
Contact Information
400 Chestnut Ridge Road
Woodcliff Lake, NJ
201 930-3300
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
